ANO6: A Drug Target / Disease Biomarker (G196527)

Target Name: ANO6

NCBI ID: G196527

ANO6

ANO6: A Drug Target / Disease Biomarker

ANO6, also known as SLC30A8, is a gene that encodes a protein known as ANO6, which is expressed in many tissues throughout the body. The ANO6 protein has been shown to play a role in a variety of physiological processes, including cell signaling, inflammation, and stress responses. As a result, ANO6 has been identified as a potential drug target and biomarker for a variety of diseases.

One of the key functions of the ANO6 protein is its role in cell signaling. The ANO6 protein is a key signaling molecule in the Wnt signaling pathway, which is a critical pathway involved in many aspects of development and growth, including cell proliferation, differentiation, and survival. The ANO6 protein helps to regulate the activity of the Wnt signaling pathway by interacting with its downstream effector, the protein Fz.

In addition to its role in cell signaling, ANO6 has also been shown to be involved in inflammation. The ANO6 protein has been shown to play a role in the regulation of immune responses and inflammation. For example, studies have shown that ANO6 can help to modulate the production of inflammatory cytokines by immune cells.

ANO6 has also been shown to be involved in stress responses. The ANO6 protein has been shown to play a role in the regulation of cellular stress responses, including the stress-induced increase in the production of stress-responsive proteins. This is important for understanding how the body responds to stress and how this response can contribute to the development of stress-related diseases.

Due to its involvement in these important biological processes, ANO6 has been identified as a potential drug target and biomarker for a variety of diseases. For example, studies have shown that ANO6 may be a useful target for the treatment of cancer, as ANO6 has been shown to play a role in the regulation of cell proliferation and survival. In addition, ANO6 has also been shown to be involved in the regulation of inflammation and stress responses, which may make it a useful target for the treatment of autoimmune diseases and other conditions that involve inflammation or stress.

In conclusion, ANO6 is a gene that encodes a protein that plays a critical role in a variety of physiological processes. As a result, ANO6 has been identified as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of ANO6 in these processes and to develop effective treatments for those who are affected by these conditions.

Protein Name: Anoctamin 6

Functions: Small-conductance calcium-activated nonselective cation (SCAN) channel which acts as a regulator of phospholipid scrambling in platelets and osteoblasts. Phospholipid scrambling results in surface exposure of phosphatidylserine which in platelets is essential to trigger the clotting system whereas in osteoblasts is essential for the deposition of hydroxyapatite during bone mineralization. Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Can generate outwardly rectifying chloride channel currents in airway epithelial cells and Jurkat T lymphocytes

The "ANO6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANO6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets